Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-cash Items (2016 - 2025)

Voyager Therapeutics' Non-cash Items history spans 11 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 83.62% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, up 83.62%, while the annual FY2025 figure was $6.4 million, 31.4% up from the prior year.
  • Non-cash Items for Q4 2025 was $6.4 million at Voyager Therapeutics, up from $3.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $11.3 million in Q4 2023 and bottomed at $247000.0 in Q2 2025.
  • The 5-year median for Non-cash Items is $3.6 million (2021), against an average of $4.6 million.
  • The largest annual shift saw Non-cash Items soared 423.18% in 2022 before it tumbled 97.39% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $1.2 million in 2021, then skyrocketed by 423.18% to $6.1 million in 2022, then skyrocketed by 85.28% to $11.3 million in 2023, then tumbled by 69.34% to $3.5 million in 2024, then surged by 83.62% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Non-cash Items are $6.4 million (Q4 2025), $3.1 million (Q3 2025), and $247000.0 (Q2 2025).